Vivasure Medical announced today that it received FDA investigational device exemption (IDE) to advance a clinical study of its PerQseal device. Additionally, Galway, Ireland-based Vivasure announced a €30 million ($32.2 million) investment from Haemonetics. It marks part of the company’s Series D financing, for which the initial $23 million tranche closed in May 2022. The […]
Vivasure Medical
Vivasure raises $23M initial Series D tranche; could reach up to $54M
Vivasure Medical announced today that it closed the first tranche — worth $23 million — of its Series D financing round. Galway, Ireland-based Vivasure’s $23 million (€22 million) fundraising tranche could make up a chunk of the Series D that could reach up to $54 million (€52 million) in total. According to a news release, […]
Vivasure treats first patient in U.S. study for next-gen PerQseal+ in TAVR procedures
Vivasure Medical announced today that the first patient was treated in a U.S. early feasibility study of its next-generation PerQseal+ device. Galway, Ireland-based Vivasure’s study will evaluate PerQseal+ in percutaneous transcatheter aortic valve replacement (TAVR) procedures. The first patient was treated by Dr. Robert Pyo at Stony Brook University Hospital in Stony Brook, New York. […]
Vivasure Medical initiates development of sutureless venous closure device
Vivasure Medical announced today that it launched a development program for its PerQseal Blue investigational product. Galway, Ireland-based Vivasure designed PerQseal Blue for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, including transcatheter mitral valve repair/replacement (TMVR) and transcatheter tricuspid valve repair/replacement (TTVR). According to a news release, the company based […]
